Abstract:Background: Doxorubicin, a first-line chemotherapeutic drug for breast cancer, kills cancer cells by inducing DNA-crosslinking damage. Dysregulated micro-RNA (miRNA) is associated with the drug resistance of tumors. However, little is known about the effect of miRNA-140-3p on DOX resistance of breast cancer. Methods: The miRNA microarray was used to sequence the transcripts of DOX-chemoresistant breast cancer tissues and DOX-chemosensitive tissues. Then, the breast cancer tissue chip in the GEO database was also analyzed to screen the target gene. Flow cytometry, in situ hybridisation (ISH), immunohistochemistry (IHC), Western blot, cell proliferation assay, real-time PCR analyses (qRT-PCR), and pull-down assay were used to explore the effects of miRNA-140-3p and programmed death ligand-1 (PD-L1) on the chemoresistance of DOX-resistant breast cancer cells treated with DOX. In vivo, the DOX-resistant breast cancer cell lines treated with miRNA-140-3p overexpression were injected subcutaneously into mice to construct breast cancer subcutaneous xenograft tumor models. Results: Based on miRNA microarray, GEO database, and bioinformatics analysis, it was found that miRNA-140-3p and PD-L1 are the core molecules in the DOX resistance regulatory network in breast cancer, and lower miRNA-140-3p and higher PD-L1 expression levels were observed in DOX-resistant breast cancer tissues and cells. IHC results showed that compared with breast cancer tissues with high miRNA-140-3p expression, PD-L1 protein expression levels in breast cancer tissues with low miRNA-140-3p were significantly higher (P<0.01). Moreover, compared with DOX-sensitive tissues, the levels of PD-L1 protein expression in DOX-resistant tissues were significantly higher (P<0.01). In in vitro and in vivo experiments, the introduction of miRNA-140-3p decreased PD-L1 expression. Mechanically, we found that the MCF-7/DOX and HS598T/DOX cells pretreated with miRNA-140-3p inhibitor or exosomes containing PD-L1 have higher stemness and lower apoptosis rate, which can be abrogated by co-treating cells with anti-PD-L1 antibody or miRNA-140-3p mimic. Conclusions: MiRNA-140-3p can suppress PD-L1 expression in breast cancer cell-derived exosomes, thereby attenuating the chemoresistance induced by DOX in breast cancer.

Mir-873 Attenuates the Stemness of Breast Cancer Cells by Directly Targeting PD-L1

MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.

The Effects of Mirnas-107 on Cell Proliferation, Senescence and Invasion of Pancreatic Cancer PANC-1 Cells

p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target

MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

The Mir-3127-5p/p-stat3 Axis Up-Regulates PD-L1 Inducing Chemoresistance in Non-Small-cell Lung Cancer

Microrna-34a Suppresses the Breast Cancer Stem Cell-Like Characteristics by Downregulating Notch1 Pathway

Microrna-873 Inhibits Self-Renewal and Proliferation of Pancreatic Cancer Stem Cells Through Pleckstrin-2-dependent PI3K/AKT Pathway.

Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer

MiR-93 Suppresses Tumorigenesis and Enhances Chemosensitivity of Breast Cancer Via Dual Targeting E2F1 and CCND1.

Mir-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer

Mir-375 Inhibits IFN-γ-induced Programmed Death 1 Ligandï¿½1 Surface Expression in Head and Neck Squamous Cell Carcinoma Cells by Blocking JAK2/STAT1 Signaling

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma

Targeting of Interleukin (IL)-17A Inhibits PDL1 Expression in Tumor Cells and Induces Anticancer Immunity in an Estrogen Receptor-Negative Murine Model of Breast Cancer

PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation